2:09 PM
 | 
Nov 28, 2018
 |  BC Extra  |  Clinical News

Critics continue to pile on as CRISPR researcher describes informed consent, review process

Jiankui He outlined the peer review and informed consent process used in the first-ever human CRISPR germline gene editing trial at the International Summit on Human Genome Editing on Wednesday. However, critics decried the process as irresponsible and opaque, while a consensus statement from the research community on next steps is expected tomorrow.

In response to questions about the ethics of the trial and review process, He said he sought input in advance on the trial design, including review by a bioethicist at Stanford University.

He also said the group used the NIH's guidelines to draft the informed consent document, which was reviewed by...

Read the full 505 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >